Designed peptides as nanomolar cross-amyloid inhibitors acting via supramolecular nanofiber co-assembly

Karin Taş, Beatrice Dalla Volta, Christina Lindner, Omar El Bounkari, Kathleen Hille, Yuan Tian, Xènia Puig-Bosch, Markus Ballmann, Simon Hornung, Martin Ortner, Sophia Prem, Laura Meier, Gerhard Rammes, Martin Haslbeck, Christian Weber, Remco T A Megens, Jürgen Bernhagen, Aphrodite Kapurniotu*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Amyloid self-assembly is linked to numerous devastating cell-degenerative diseases. However, designing inhibitors of this pathogenic process remains a major challenge. Cross-interactions between amyloid-β peptide (Aβ) and islet amyloid polypeptide (IAPP), key polypeptides of Alzheimer's disease (AD) and type 2 diabetes (T2D), have been suggested to link AD with T2D pathogenesis. Here, we show that constrained peptides designed to mimic the Aβ amyloid core (ACMs) are nanomolar cross-amyloid inhibitors of both IAPP and Aβ42 and effectively suppress reciprocal cross-seeding. Remarkably, ACMs act by co-assembling with IAPP or Aβ42 into amyloid fibril-resembling but non-toxic nanofibers and their highly ordered superstructures. Co-assembled nanofibers exhibit various potentially beneficial features including thermolability, proteolytic degradability, and effective cellular clearance which are reminiscent of labile/reversible functional amyloids. ACMs are thus promising leads for potent anti-amyloid drugs in both T2D and AD while the supramolecular nanofiber co-assemblies should inform the design of novel functional (hetero-)amyloid-based nanomaterials for biomedical/biotechnological applications.

Original languageEnglish
Article number5004
Number of pages22
JournalNature Communications
Volume13
Issue number1
DOIs
Publication statusPublished - 25 Aug 2022

Keywords

  • Alzheimer Disease/drug therapy
  • Amyloid/pharmacology
  • Amyloid beta-Peptides/chemistry
  • Amyloidogenic Proteins
  • Amyloidosis
  • Diabetes Mellitus, Type 2/drug therapy
  • Humans
  • Islet Amyloid Polypeptide/chemistry
  • Nanofibers

Cite this